Is Targeted Protein Degradation the “Break” Neurology Needs?
In this webinar, The post Is Targeted Protein Degradation the “Break” Neurology Needs? appeared first on GEN - Genetic Engineering and Biotechnology News .
Angela M. Cacace, PhD, Chief Scientific Officer of Arvinas, leads efforts to advance targeted protein degradation in neurology. As Senior Vice President of Neuroscience and Platform Biology, she has overseen the development of Arvinas' PROTAC Discovery Engine, which targets novel E3 ligases and crosses the blood-brain barrier for neurologic diseases.
At Fulcrum Therapeutics, she built a biology platform, cultivated scientific teams, and developed candidate therapeutics. Previously at Bristol Myers Squibb, she spearheaded alternative therapies and co-invented several development candidates. Now a Board member of BioCT, Dr. Cacace cites recent LRRK2 protein degrader data as evidence of renewed optimism for neurodegenerative diseases, explaining how protein degradation could provide more precise modulation of disease biology and open new avenues across these conditions. A Q&A session follows the presentation, inviting audience questions for the expert panelists.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
